pyrazinamide has been researched along with Hepatitis E in 1 studies
pyrazinecarboxamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis.
Hepatitis E: Acute INFLAMMATION of the LIVER in humans; caused by HEPATITIS E VIRUS, a non-enveloped single-stranded RNA virus. Similar to HEPATITIS A, its incubation period is 15-60 days and is enterically transmitted, usually by fecal-oral transmission.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kumar, R | 1 |
| Bhatia, V | 1 |
| Khanal, S | 1 |
| Sreenivas, V | 1 |
| Gupta, SD | 1 |
| Panda, SK | 1 |
| Acharya, SK | 1 |
1 other study available for pyrazinamide and Hepatitis E
| Article | Year |
|---|---|
Antituberculosis therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Female; Hepatitis E; Humans; Indi | 2010 |